Etanercept and neoplasms
The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis. TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the...
Gespeichert in:
| Veröffentlicht in: | Actas dermo-sifiliográficas (English ed.) 2010-05, Vol.101 Suppl 1, p.88 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 88 |
| container_title | Actas dermo-sifiliográficas (English ed.) |
| container_volume | 101 Suppl 1 |
| creator | García-Rabasco, A Sánchez-Carazo, J L Esteve, A |
| description | The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis. TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature. We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept. In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out. |
| doi_str_mv | 10.1016/S0001-7310(10)70015-6 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_20492887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20492887</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-8f207696a16a30080556b4ef4a6ceb67484ac4f12fcae6828051cb61d343324b3</originalsourceid><addsrcrecordid>eNo1jk1LAzEURYMgttTuu6l0qYvoe_l4ySylVFsouFDX5SWTgNIZw2Rc-O-tqKvDhcPlCLFEuEVAunsGAJROI1wj3LjTsJLOxBSt81JhAxMxr_X9x1KorcYLMVFgGuW9m4rFZuQ-DTGVccV9u-rTRzly7eqlOM98rGn-x5l4fdi8rLdy__S4W9_vZUHwo_RZgaOGGIk1gAdrKZiUDVNMgZzxhqPJqHLkRF6dBIyBsNVGa2WCnomr39_yGbrUHsrw1vHwdfhP1N_7RzsN</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Etanercept and neoplasms</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Alma/SFX Local Collection</source><creator>García-Rabasco, A ; Sánchez-Carazo, J L ; Esteve, A</creator><creatorcontrib>García-Rabasco, A ; Sánchez-Carazo, J L ; Esteve, A</creatorcontrib><description>The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis. TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature. We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept. In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out.</description><identifier>EISSN: 1578-2190</identifier><identifier>DOI: 10.1016/S0001-7310(10)70015-6</identifier><identifier>PMID: 20492887</identifier><language>spa</language><publisher>Spain</publisher><subject>Adenocarcinoma - chemically induced ; Adult ; Breast Neoplasms - chemically induced ; Decision Trees ; Etanercept ; Female ; Humans ; Immunoglobulin G - adverse effects ; Psoriasis - drug therapy ; Receptors, Tumor Necrosis Factor ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Actas dermo-sifiliográficas (English ed.), 2010-05, Vol.101 Suppl 1, p.88</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20492887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García-Rabasco, A</creatorcontrib><creatorcontrib>Sánchez-Carazo, J L</creatorcontrib><creatorcontrib>Esteve, A</creatorcontrib><title>Etanercept and neoplasms</title><title>Actas dermo-sifiliográficas (English ed.)</title><addtitle>Actas Dermosifiliogr</addtitle><description>The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis. TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature. We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept. In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out.</description><subject>Adenocarcinoma - chemically induced</subject><subject>Adult</subject><subject>Breast Neoplasms - chemically induced</subject><subject>Decision Trees</subject><subject>Etanercept</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - adverse effects</subject><subject>Psoriasis - drug therapy</subject><subject>Receptors, Tumor Necrosis Factor</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>1578-2190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jk1LAzEURYMgttTuu6l0qYvoe_l4ySylVFsouFDX5SWTgNIZw2Rc-O-tqKvDhcPlCLFEuEVAunsGAJROI1wj3LjTsJLOxBSt81JhAxMxr_X9x1KorcYLMVFgGuW9m4rFZuQ-DTGVccV9u-rTRzly7eqlOM98rGn-x5l4fdi8rLdy__S4W9_vZUHwo_RZgaOGGIk1gAdrKZiUDVNMgZzxhqPJqHLkRF6dBIyBsNVGa2WCnomr39_yGbrUHsrw1vHwdfhP1N_7RzsN</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>García-Rabasco, A</creator><creator>Sánchez-Carazo, J L</creator><creator>Esteve, A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201005</creationdate><title>Etanercept and neoplasms</title><author>García-Rabasco, A ; Sánchez-Carazo, J L ; Esteve, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-8f207696a16a30080556b4ef4a6ceb67484ac4f12fcae6828051cb61d343324b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2010</creationdate><topic>Adenocarcinoma - chemically induced</topic><topic>Adult</topic><topic>Breast Neoplasms - chemically induced</topic><topic>Decision Trees</topic><topic>Etanercept</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - adverse effects</topic><topic>Psoriasis - drug therapy</topic><topic>Receptors, Tumor Necrosis Factor</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Rabasco, A</creatorcontrib><creatorcontrib>Sánchez-Carazo, J L</creatorcontrib><creatorcontrib>Esteve, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Actas dermo-sifiliográficas (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Rabasco, A</au><au>Sánchez-Carazo, J L</au><au>Esteve, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etanercept and neoplasms</atitle><jtitle>Actas dermo-sifiliográficas (English ed.)</jtitle><addtitle>Actas Dermosifiliogr</addtitle><date>2010-05</date><risdate>2010</risdate><volume>101 Suppl 1</volume><spage>88</spage><pages>88-</pages><eissn>1578-2190</eissn><abstract>The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis. TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature. We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept. In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out.</abstract><cop>Spain</cop><pmid>20492887</pmid><doi>10.1016/S0001-7310(10)70015-6</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1578-2190 |
| ispartof | Actas dermo-sifiliográficas (English ed.), 2010-05, Vol.101 Suppl 1, p.88 |
| issn | 1578-2190 |
| language | spa |
| recordid | cdi_pubmed_primary_20492887 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - chemically induced Adult Breast Neoplasms - chemically induced Decision Trees Etanercept Female Humans Immunoglobulin G - adverse effects Psoriasis - drug therapy Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Etanercept and neoplasms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T23%3A43%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etanercept%20and%20neoplasms&rft.jtitle=Actas%20dermo-sifiliogr%C3%A1ficas%20(English%20ed.)&rft.au=Garc%C3%ADa-Rabasco,%20A&rft.date=2010-05&rft.volume=101%20Suppl%201&rft.spage=88&rft.pages=88-&rft.eissn=1578-2190&rft_id=info:doi/10.1016/S0001-7310(10)70015-6&rft_dat=%3Cpubmed%3E20492887%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20492887&rfr_iscdi=true |